Beth Scott

Background

About Beth Scott

As Vice President of Medical Affairs in Ophthalmology, I bring over 18 years of experience in medical affairs, clinical development, regulatory strategy, and product lifecycle management for ophthalmic therapies. I have guided the successful launch of five blockbuster products, including biologics and first-in-class treatments, by focusing on strategic market positioning and regulatory compliance. I excel in building and leading high-impact, cross-functional teams to deliver comprehensive evidence generation strategies across clinical trials and real-world studies. My expertise combines scientific rigor with commercial insights, enhancing product differentiation, maximizing value proposition to attain market access and establish favorable reimbursement, driving meaningful engagement with global stakeholders. In global regulatory affairs, I designed successful approval pathways for complex submissions and negotiations to achieve timely drug, device and combination product approvals and optimize market access, adapting to evolving regulatory landscapes. My work includes developing launch readiness plans, overseeing field medical teams, and fostering cross-disciplinary partnerships for enhanced outcomes. I have established strategic partnerships with key opinion leaders, academic institutions, and industry partners to drive innovation and expand the reach of ophthalmic therapies. My strategic focus has resulted in valuable collaborations, strengthened pipelines, and improved educational and research initiatives within the fields of Thyroid Eye Disease, Glaucoma, Retinal Disease, Dry Eye, Presbyopia, and Myopia My approach is centered on data-driven decision-making and evidence-based strategies that enhance both clinical and market leadership. I am adept at scientific communication and value-driven engagement, advancing organizational goals and improving patient care standards. I am a valued strategic partner in the matrix organization that consistently delivers growth for the brand and company. A strategic and results-oriented leader, I am committed to advancing ophthalmology through innovative medical strategies, robust clinical development, impactful evidence generation, and leadership that combines scientific excellence with business growth